By Stephen V. Liu, MD Posted: March 1, 2019 Dr. Stephen V. Liu The addition of atezolizumab to standard chemotherapy for extensive-stage SCLC achieved what, for decades, had been beyond […] Read more
Posted: March 1, 2019 In the following interview, Jamie E. Chaft, MD, a medical oncologist at the Memorial Sloan Kettering Cancer Center, discusses new data on induction immunotherapy for patients […] Read more
This article is the first in a two-part series on ongoing challenges using immunotherapy in special populations. The second part of this series focuses on elderly patients. By Valérie Gounant, MD, and […] Read more
Posted: December 2018 In the following interview, Vassiliki A. Papadimitrakopoulou, MD, Jay and Lori Eisenberg Distinguished Professor of Medicine and section chief of Thoracic Medical Oncology at the University of […] Read more
By Ross Soo, MB BS, PhD, FRACP Posted: December 2018 The treatment of patients with advanced NSCLC harbouring an actionable oncogene with tyrosine kinase inhibitors (TKIs) directed at its oncogenic […] Read more
By Mariano Provencio-Pulla, MD, PhD Posted: December 2018 Patients with stage IIIA NSCLC with clinically evident N2 nodal spread have an overall 5-year survival rate of only 10% to 15%. […] Read more
By Kara Nyberg, PhD Posted: August 2018 The pace of research focused on new therapies for advanced NSCLC has progressed from a trot to a sprint in recent years. Among […] Read more
By D. Ross Camidge, MD, and Mary W. Redman, PhD Posted: August 2018 Updates of the primary analysis of the phase III ALEX trial were presented at the American Society […] Read more
By Kara Nyberg, PhD Posted: August 2018 Treatment advances for metastatic squamous cell carcinoma have long lagged behind those for other NSCLC subtypes, forcing patients with this difficult-to-treat disease to […] Read more
By Corey Langer, MD, IASLC Lung Cancer News Editor Posted: June 2018 The therapeutic landscape irrevocably altered on April 17, 2018, when three pivotal trials—KEYNOTE 189, CheckMate 227 and Impower […] Read more